Guillain-Barré syndrome and other autoimmune neurophaties : current therapy
Guillain-Barré syndrome (GBS) is characterized by rapidly progressive and generally ascending symmetrical muscle weakness, accompanied by decreased or absent osteotendinous reflexes. The inflammatory process may affect the myelin or the axon. There are 4 clinical forms of GBS: 1) acute inflammatory demyelinating polyradiculoneuropathy, 2) acute motor axonal neuropathy, 3) acute sensory and motor axonal neuropathy, and 4) the Miller-Fisher variant, which is characterized by ophthalmoplegia, ataxia and areflexia, with little muscle weakness. Diagnosis is based on the albumin-cytological dissociation observed at the end of the first week after the onset of symptoms and may persist until the third week, as well as on the specific neurophysiological alterations of each clinical form. The treatment of GBS will depend on the degree of severity, if the patient presents grade IV or less according to the Paradiso scale, it will be treated with Ig IV, if it presents grade V, the use of plasmapheresis and/or immunoadbosorption is recommended. In severe axonal cases, the use of corticosteroid bolus is recommended in initial stages. There is a clinical picture that overlaps GBS and chronic demyelinating polyneuropathy related to antibodies against neurophysin and contactin, in this case the appropriate therapy is rituximab.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 Suppl 3 |
|---|---|
| Enthalten in: |
Medicina - 82 Suppl 3(2022) vom: 30. Aug., Seite 82-88 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Síndrome de Guillain-Barré y otras neuropatías autoinmunes: tratamiento actual |
|---|
| Beteiligte Personen: |
Expósito, Jesica [VerfasserIn] |
|---|
| Themen: |
Congress |
|---|
| Anmerkungen: |
Date Completed 07.09.2022 Date Revised 07.09.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM345721012 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345721012 | ||
| 003 | DE-627 | ||
| 005 | 20231226025721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||spa c | ||
| 028 | 5 | 2 | |a pubmed24n1152.xml |
| 035 | |a (DE-627)NLM345721012 | ||
| 035 | |a (NLM)36054864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Expósito, Jesica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guillain-Barré syndrome and other autoimmune neurophaties |b current therapy |
| 246 | 3 | 3 | |a Síndrome de Guillain-Barré y otras neuropatías autoinmunes: tratamiento actual |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2022 | ||
| 500 | |a Date Revised 07.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Guillain-Barré syndrome (GBS) is characterized by rapidly progressive and generally ascending symmetrical muscle weakness, accompanied by decreased or absent osteotendinous reflexes. The inflammatory process may affect the myelin or the axon. There are 4 clinical forms of GBS: 1) acute inflammatory demyelinating polyradiculoneuropathy, 2) acute motor axonal neuropathy, 3) acute sensory and motor axonal neuropathy, and 4) the Miller-Fisher variant, which is characterized by ophthalmoplegia, ataxia and areflexia, with little muscle weakness. Diagnosis is based on the albumin-cytological dissociation observed at the end of the first week after the onset of symptoms and may persist until the third week, as well as on the specific neurophysiological alterations of each clinical form. The treatment of GBS will depend on the degree of severity, if the patient presents grade IV or less according to the Paradiso scale, it will be treated with Ig IV, if it presents grade V, the use of plasmapheresis and/or immunoadbosorption is recommended. In severe axonal cases, the use of corticosteroid bolus is recommended in initial stages. There is a clinical picture that overlaps GBS and chronic demyelinating polyneuropathy related to antibodies against neurophysin and contactin, in this case the appropriate therapy is rituximab | ||
| 650 | 4 | |a Congress | |
| 650 | 4 | |a Guillan-Barré | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a immunoadsorption | |
| 650 | 4 | |a immunoglobulins | |
| 650 | 4 | |a plasmapheresis | |
| 700 | 1 | |a Carrera, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Natera, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Nolasco, Gregorio |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimiento, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Ortez, Carlos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina |d 1945 |g 82 Suppl 3(2022) vom: 30. Aug., Seite 82-88 |w (DE-627)NLM000007854 |x 1669-9106 |7 nnns |
| 773 | 1 | 8 | |g volume:82 Suppl 3 |g year:2022 |g day:30 |g month:08 |g pages:82-88 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 Suppl 3 |j 2022 |b 30 |c 08 |h 82-88 | ||